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NCCN Guidelines Insights

Overview
Lung cancer is the leading cause of cancer death in the United States. 1 In 2018, an estimated 234,030 new cases of lung and bronchial cancer will be diagnosed and 154,050 deaths will occur. 2, 3 However, quality of life and progression-free survival (PFS) have improved for patients with advanced non-small cell lung cancer (NSCLC) who have specific predictive biomarkers and receive targeted therapy or immunotherapy compared with those receiving chemotherapy.
4-9 These NCCN Guidelines Insights focus on recent updates in targeted therapy and immunotherapy for patients with advanced NSCLC. For a list of the 2018 updates, see the complete version of the NCCN Guidelines for NSCLC (available at NCCN.org). The NCCN Guidelines for NSCLC address all aspects of disease management.
Biomarkers
A predictive biomarker is correlated with therapeutic efficacy based on the mechanism of action between the therapy and the biomarker. A prognostic biomarker is indicative of patient survival independent of treatment received, because the biomarker is an indicator of the innate tumor aggressiveness. For the 2018 update, a new section was added to the NCCN Guidelines that discusses key established biomarkers and appropriate testing methods to identify them (see NSCL-G, pages 815-818).
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Key established predictive biomarkers include ALK rearrangements, ROS1 rearrangements, sensitizing EGFR mutations, BRAF V600E point mutations, and PD-L1 expression levels (see NSCL-G, pages 815-818, and "Established Biomarkers," following section). The NCCN panel recommends testing for these key established biomarkers in patients with advanced NSCLC before initial treatment, because effective targeted therapy or immunotherapy is available. The panel strongly advises broader molecular profiling to assess for emerging biomarkers (see NSCL-17, page 809, and "Emerging Biomarkers," page 816).
Established Biomarkers
ALK Rearrangements: Approximately 5% of patients with NSCLC have ALK rearrangements; these patients tend to have adenocarcinoma histology and be never-smokers or light smokers. 11, 12 The NCCN panel recommends testing for ALK rearrangements (category 1 recommendation) based on the efficacy of alectinib, crizotinib, and ceritinib (see NSCL-17, page 809). Two tests have been FDA-approved for stand-alone testing or rapid prescreening: (1) a fluorescence in situ hybridization (FISH) diagnostic test, and (2) an immunohistochemistry assay. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Next-generation sequencing (NGS) can be used if the platform has been appropriately designed and validated. [23] [24] [25] [26] [27] Initial ALK-Directed Therapy: Alectinib is an oral tyrosine kinase inhibitor (TKI) that inhibits ALK rearrangements. 28 advanced NSCLC, including those with asymptomatic central nervous system (CNS) disease. 28 Disease progression or death occurred in fewer patients receiving alectinib (41% [62/152] [75/151] , respectively), although patients received alectinib for a longer duration than crizotinib (median, 17.9 vs 10.7 months). Two treatment-related deaths were reported for crizotinib, and none were reported for alectinib.
A phase III randomized trial (J-ALEX) assessed first-line therapy with alectinib versus crizotinib in 207 Japanese patients with ALK-positive advanced NSCLC, with results similar to the ALEX trial. 5 The NCCN panel recommends alectinib as a preferred first-line treatment (category 1) for ALKpositive metastatic NSCLC based on these clinical trials and FDA approval (see NSCL-21, page 810). Two other ALK inhibitors, crizotinib and ceritinib, are also recommended (category 1 for both) by the panel for first-line therapy in patients with ALK-positive NSCLC based on clinical trial data and FDA approvals. 6, 29, 30 Subsequent Therapy: Patients typically experience disease progression after initial therapy with NCCN Guidelines Insights alectinib, crizotinib, or ceritinib; second-line or beyond (ie, subsequent) therapy recommendations depend on the mechanism of resistance to therapy (see NSCL-22 and NSCL-23, pages 811 and 812).
For patients who experience progression on firstline crizotinib, subsequent therapy for ALK-positive NSCLC includes alectinib, ceritinib, or brigatinib; continuing crizotinib is also an option, depending on the type of progression (see NSCL-22, page 811). [31] [32] [33] [34] [35] For patients who experience progression on first-line alectinib or ceritinib, recommended subsequent therapy for ALK-positive NSCLC includes the initial cytotoxic chemotherapy regimens (eg, carboplatin/pemetrexed for nonsquamous NSCLC) used for first-line treatment in patients without genetic alterations, depending on type of progression (see NSCL-23, above). 36, 37 Molecular testing of a biopsy to review the resistance mechanism in this scenario may be beneficial to determine the role of other ALK inhibitors. Continuing alectinib or ceritinib may also be appropriate for some patients who experience progression on alectinib or ceritinib (see NSCL-23, above). 38 In tumors with an actionable mutation, such as ALK rearrangements, immunotherapy appears to be less effective (regardless of PD-L1 expression levels) based on data in the second-line setting. [39] [40] [41] [42] Ongoing studies are assessing the role of individual ALK kinase domain mutations in selecting subsequent therapy. 43, 44 ROS1 Rearrangements: Although ROS1 is a distinct receptor tyrosine kinase, it is very similar to ALK. 45, 46 ROS1 rearrangements occur in approximately 1% to 2% of patients with NSCLC, and occur more frequently in younger women (median age, 50 years) with adenocarcinoma who are never-smokers and in those negative for EGFR and KRAS mutations and ALK rearrangements. 46 NSCL-G, pages 815-818). 13,48,52-54 NGS can also be used if the platform has been appropriately designed and validated. [23] [24] [25] [26] [27] 46 Immunohistochemistry testing for ROS1 requires confirmation of all positives due to a low specificity of the testing methodology. A single companion diagnostic test has been FDA-approved for ROS1 rearrangements; however, clinicians may use any appropriately validated test. First-Line Therapy: Crizotinib inhibits ROS1 rearrangements and is FDA-approved for patients with locally advanced or metastatic ROS1-positive NSCLC. 6, 29, 50, [55] [56] [57] [58] [59] Crizotinib is very effective for patients with ROS1 rearrangements, yielding response rates of approximately 70% to 80%, including complete responses (CRs). 46, 50, 51 In 50 patients with ROS1-positive advanced NSCLC, crizotinib yielded an objective response rate of 72% (95% CI, 58-84), with 3 CRs and 33 partial responses (PRs). 46 The median duration of response was 17.6 months (95% CI, 14.5 months to not reached), and the median PFS was 19.2 months (95% CI, 14.4 months to not reached). Another study assessed crizotinib in 30 patients with ROS1-positive stage IV NSCLC. 50 There were 5 CRs (overall response rate [ORR], 80%; disease control rate, 86.7%), and median PFS was 9.1 months. Many patients (n=26) received pemetrexed (either alone or in combination with platinum, and either before or after crizotinib) and had a response rate of 57.7% and a median PFS of 7.2 months. For the 2018 guideline update, the NCCN panel voted that crizotinib is the preferred agent for patients with ROS1-positive NSCLC based on trial data and the FDA approval (see NSCL-24, above).
Ceritinib is an oral TKI that inhibits ROS1 rearrangements. 60 A phase II trial assessed ceritinib as first-line therapy in patients (n=28 evaluable) with ROS1-positive NSCLC. 60 One CR and 19 PRs (ORR, 62%; 95% CI, 45%-77%) were reported. PFS was 19.3 months (95% CI, 1-37 months) for crizotinib-naïve patients and 9.3 months (95% CI, 0-22 months) for all patients; median overall sur-NCCN Guidelines Insights Alectinib and ceritinib are not recommended in patients with ROS1-positive NSCLC whose disease becomes resistant to crizotinib, because no trial data suggest that these agents would be effective in this setting. 46 In patients with biomarkers who have progressed on targeted therapy, immunotherapy appears to be less effective (regardless of PD-L1 expression levels). [39] [40] [41] [42] Ongoing studies are assessing new agents for patients with ROS1-positive NSCLC whose disease becomes resistant to crizotinib.
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BRAF V600E Mutations: BRAF is a serine/threonine kinase that is part of the MAP/ERK signaling pathway. BRAF V600E is the most common of the BRAF point mutations, occurring in 1% to 2% of patients with lung adenocarcinoma who are typically current or former smokers. [65] [66] [67] BRAF mutations typically do not overlap with EGFR mutations or ALK rearrangements. 65, 68 The NCCN panel recommends testing for BRAF mutations based on data showing the efficacy of dabrafenib/trametinib (see NSCL-17, page 809). 65, 68 Real-time PCR, Sanger sequencing, and NGS are the most commonly used methods to assess for BRAF mutations (see NSCL-G, pages 815-818).
Dabrafenib and trametinib inhibit kinases in the RAS/RAF/MEK/ERK pathway. 65, 68 Dabrafenib inhibits BRAF harboring V600E mutations; trametinib inhibits MEK 1/2, which is downstream of BRAF signaling. A phase II trial assessed first-line NCCN Guidelines Insights Although tumor testing has been primarily focused on use of formalin-fi xed paraffi n-embedded (FFPE) tissues, increasingly, laboratories accept other specimen types, notably cytopathology smear preparations. A major limitation in obtaining molecular testing results for NSCLC occurs when minimally invasive techniques are used to obtain samples; the yield may be insuffi cient for molecular, biomarker, and histologic testing. Therefore, bronchoscopists and interventional radiologists should procure suffi cient tissue to enable all appropriate testing. When tissue is minimal, laboratories should deploy techniques to maximize tissue for molecular and ancillary testing, including dedicated histology protocols for small biopsies, including "up-front" slide sectioning for diagnostic and predictive testing.
• Testing Methodologies
Appropriate possible testing methodologies are indicated below for each analyte separately; however, several methodologies are generally considerations for use: ◊ Real-time polymerase chain reaction (PCR) can be used in a highly targeted fashion (specifi c mutations targeted). When this technology is deployed, only those specifi c alterations that are targeted by the assay are assessed.
◊ Sanger sequencing requires the greatest degree of tumor enrichment. Unmodifi ed Sanger sequencing is not appropriate for detection of mutations in tumor samples with less than 25% to 30% tumor after enrichment and is not appropriate for assays in which identifi cation of subclonal events (eg, resistance mutations) is important. If Sanger sequencing is utilized, tumor enrichment methodologies are nearly always recommended. ◊ Next-generation sequencing (NGS) is increasingly utilized in clinical laboratories. Not all types of alterations are detected by individual NGS assays and it is important to be familiar with the types of alterations identifi able in individual assays or combination(s) of assays. ◊ Other methodologies may be utilized, including multiplex approaches not listed above (ie, SNaPshot, MassARRAY). ◊ Fluorescence in situ hybridization (FISH) analysis is utilized for many assays examining copy number, amplifi cation, and structural
alterations such as gene rearrangements. ◊ Immunohistochemistry (IHC) is specifi cally utilized for some specifi c analytes, and can be a useful surrogate or screening assay for others. Continued combination therapy with dabrafenib/trametinib for 36 patients with metastatic NSCLC and BRAF V600E mutations. 69 The ORR was 64% (n=23; 95% CI, 46-79) with 2 CRs, and median PFS was 10.9 months (95% CI, 7.0-16.6 months). Many patients (69%; n=25) had ≥1 grade 3 or 4 AEs. Serious AEs included increased alanine aminotransferase level (14%; n=5), pyrexia (11%; n=4), increased aspartate aminotransferase level (8%; n=3), and decreased ejection fraction (8%; n=3).
A phase II study assessed subsequent therapy with the dabrafenib/trametinib regimen in 57 patients with advanced NSCLC and BRAF V600E mutations whose disease had progressed on chemotherapy. 65, 70 The response rate was 63% (n=36) with dabrafenib/ trametinib; PFS was 9.7 months (95% CI, 6.9-19.6). Serious AEs occurred in 56% of patients (n=32), including pyrexia, anemia, confusional state, hemoptysis, hypercalcemia, and cutaneous squamous cell carcinoma. Common grade 3 to 4 AEs included neutropenia in 9% (n=5), hyponatremia in 7% (n=4), and anemia in 5% (n=3). Four patients died of retroperitoneal hemorrhage, subarachnoid hemorrhage, respiratory distress, or severe disease progression. Preliminary updated data showed that patients receiving dabrafenib/trametinib had a median OS of 18.2 months (95% CI, 14.3 months to not estimable). 71 Based on these trials and the FDA approval, the NCCN Guidelines Panel recommends first-line or subsequent therapy with dabrafenib/trametinib in patients with metastatic NSCLC and BRAF V600E mutations (see NSCL-25, page 814). 69, 71, 72 Firstline or subsequent chemotherapy regimens are also recommended options using the same initial cytotoxic regimens recommended for patients without genetic alterations (eg, carboplatin/pemetrexed for nonsquamous disease). Single-agent therapy with dabrafenib or vemurafenib is also an option for patients with BRAF V600E mutations who cannot tolerate combination therapy with dabrafenib/ trametinib. NCCN Guidelines Insights 
Emerging Biomarkers
The NCCN Guidelines recommend broad-based molecular testing to assess for rare driver mutations for which effective drugs may be available (even if not yet FDA-approved for lung cancer), or to counsel patients regarding the availability of clinical trials in addition to assessing for established biomarkers. Emerging rare driver mutations include HER2 mutations (ie, ERBB2 mutations), RET rearrangements, high-level MET amplification, or MET exon 14 skipping mutations (see "Emerging Targeted Agents for Patients With Genetic Alterations" in the complete version of the NCCN Guidelines [NSCL-H]). Clinical trials are currently in progress for other emerging biomarkers; for example, new targeted agents are being assessed for effectiveness in patients with NTRK fusions.
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Immunotherapy
The NCCN panel recommends first-line pembrolizumab/carboplatin (or cisplatin)/pemetrexed (category 1) for patients with advanced nonsquamous NSCLC (ie, adenocarcinoma, large cell carcinoma) or NSCLC not otherwise specified based on data from phase II and III trials and on the FDA approval (pembrolizumab/carboplatin/ pemetrexed). 76, 77 Pembrolizumab/chemotherapy is recommended for patients without (or unknown) genetic alterations whose PD-L1 levels are <50% or unknown. Most patients received pembrolizumab/ carboplatin/pemetrexed (72%; n=445), but some received pembrolizumab/cisplatin/pemetrexed (28%; n=171); patients did not have EGFR mutations or ALK rearrangements. The estimated OS rate at 1 year was 69.2% (95% CI, 64.1-73.8) for pembrolizumab/ chemotherapy versus 49.4% (95% CI, 42.1-56.2) for chemotherapy alone (HR for death, 0.49; 95% CI, 0.38-0.64; P<.001) after a median follow-up of 10.5 months. OS was improved regardless of PD-L1 expression levels, although most patients (63%) had levels of ≥1%. Median PFS was 8.8 months (95% CI, 7.6-9.2 months) for pembrolizumab/chemotherapy NCCN Guidelines Insights The NCCN panel also added a first-line therapy recommendation (category 2A) for carboplatin/paclitaxel (or nab-paclitaxel)/pembrolizumab for patients with metastatic squamous cell NSCLC based on preliminary data from the phase III KEYNOTE-407 trial. 79 This pembrolizumab/chemotherapy regimen is recommended for patients whose PD-L1 levels are <50% or unknown. Maintenance therapy with pembrolizumab is also a recommended option (category 2A). Patients receiving pembrolizumab/chemotherapy had an overall response rate of 58.4% compared with 35.0% in those receiving chemotherapy alone (P=.0004). NCCN Guidelines Insights each checkpoint inhibitor therapy. The potential for multiple different assays for PD-L1 has raised concern among both pathologists and oncologists. ALK fusions: IHC assays for ALK can serve as a screening modality for further ALK testing, and can alternatively be used as a stand-alone test to determine eligibility for ALK TKI. An FDA-approved IHC assay for ALK is available. ROS1 fusions: IHC assays for ROS1 should only be deployed as a screening modality for further ROS1 testing, because the specifi city of a positive result is low. Positive ROS1 IHC should not be utilized to select patients for TKI therapy without additional confi rmatory testing. Currently there is not an FDA-approved IHC assay for ROS1. BRAF p.V600E mutations: An antibody specifi c to the p.V600E mutation is available. Some studies have examined utilization of this antibody in cases of NSCLC; however, optimization of this antibody may be tumor-specifi c and care should be exercised when using this approach. EGFR mutations: Limited mutation-specifi c antibodies are available for EGFR. While these antibodies have good specifi city, the sensitivity is lacking, and it is not recommended to use EGFR mutation-specifi c antibodies except in circumstances of extremely limited tissue, because many sensitizing EGFR mutations are not detected with this approach.
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Summary
The NCCN Guidelines for NSCLC address all aspects of disease management. These NCCN Guidelines Insights focus on recent updates to targeted therapy for patients with advanced NSCLC who have ALK or ROS1 rearrangements or BRAF V600E mutations. For the 2018 guideline update, the panel recommends crizotinib as a preferred agent for patients with ROS1 rearrangements. The panel also recommends ceritinib (category 2A) for patients with ROS1-positive advanced NSCLC. A new section was added that describes key established biomarkers and appropriate testing to identify patients with these biomarkers. The NCCN panel also revised the recommendation for pembrolizumab/carboplatin (or cisplatin)/pemetrexed to category 1 (from category 2A) based on recent trial data. 78, 79 In addition, the following regimens are now recommended: (1) atezolizumab/carboplatin/paclitaxel/bevacizumab (category 1) as first-line therapy for patients with metastatic nonsquamous NSCLC; and (2) pembrolizumab/carboplatin/paclitaxel (or nab-paclitaxel) (category 2A) as first-line therapy for patients with metastatic squamous cell carcinoma.
For a list of all 2018 updates, see the complete NCCN Guidelines for NSCLC (available at NCCN.org).
